Milano, Italy. In Eur J Intern Med, 10 May 2015
Recent studies have demonstrated that ECD patients bare mutations in the proto-oncogene BRAF (and more rarely in other genes involved in the MAPK activation pathway), suggesting a critical role of this pathway in the pathogenesis and a possible clonal origin of the disease.
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Tokyo, Japan. In Transl Lung Cancer Res, 30 Apr 2015
Fusions of the RET and ROS1 protein tyrosine kinase oncogenes with several partner genes were recently identified as new targetable genetic aberrations in cases of non-small cell lung cancer (NSCLC) lacking activating EGFR, KRAS, ALK, BRAF, or HER2 oncogene aberrations.
BRAF mutations in non-small cell lung cancer.
Sydney, Australia. In Transl Lung Cancer Res, 30 Apr 2015
BACKGROUND: BRAF is a proto-oncogene encoding a serine/threonine protein kinase which promotes cell proliferation and survival.